Clinical trial · Interventional
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
A Phase 1b Dose Escalation, Open-label Study Of CP-751,871 In Combination With Docetaxel In Advanced Non-hematologic Malignancies
NCT01653158CI-TRIAL-00012484completedPhase 1Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This clinical trial is designed to determine the safety, tolerability, pharmacokinetics and pharmacodynamic effects of escalating doses of CP 751,871 given in combination with docetaxel in patients with non-hematologic malignancies for whom docetaxel is a reasonable treatment option.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Non-Hematologic Malignancies | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CP-751,871 | Drug | — | UNRESOLVED |
| Docetaxel | Drug | Docetaxel | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CP-751,871 combined with docetaxel
- interventionNames
- Drug: CP-751,871
- Drug: Docetaxel
Primary outcomes (14)
- measure
- Maximum Tolerated Dose (MTD)
- timeFrame
- Cycle 1 Day 1 through Cycle 1 Day 21
- measure
- Recommended Phase 2 Dose (RP2D)
- timeFrame
- Cycle 1 Day 1 through Cycle 1 Day 21
- measure
- Area Under the Curve From Time Zero to 25 Hours Postdose (AUC25) of Docetaxel in Cycle 1
- timeFrame
- 30 minutes before docetaxel infusion; 30 and 50 minutes after the start of docetaxel infusion; and 30 minutes and 1, 3, 8, and 24 hours after the end of docetaxel infusion
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age greater than 18 years * Documented advanced-stage non-hematologic malignancy for whom docetaxel monotherapy is a reasonable treatment option * Eastern Cooperative Oncology Group \[ECOG\] performance status 0-1 Exclusion Criteria: * Significant active cardiac disease * Chemotherapy, biological or investigational agents within 4 weeks prior to dosing * Inadequate bone marrow, renal, cardiac or liver function
References
Publications (0)
Data not yet available
No reference posted for this study.